Bernstein analyst Lance Wilkes downgraded Agilon Health (AGL) to Market Perform from Outperform with a price target of $1.40, down from $4. The firm cites the company’s worse than expected margin pressure for the downgrade. Agilon’s margin challenges reduce its capital cushion and increases its cost of capital, which creates an uncertain growth outlook, the analyst tells investors in a research note. Bernstein does not see the company as representing a strategically valuable asset that could be attractive to buyers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
- Agilon Health price target lowered to $1.10 from $2.40 at Jefferies
- Agilon Health price target lowered to $1 from $5 at Baird
- Agilon Health’s Earnings Call: Challenges and Optimism
- Agilon Health Faces Uncertainty Amid RAF Challenges and Leadership Changes